(Q34437164)

2 August 2017

title

Baseline predictors for one-year visual outcomes with ranibizumab or bevacizumab for neovascular age-related macular degeneration (English)

1 reference

2 August 2017

1 reference

Ebenezer Daniel

7

0 references

Cynthia A Toth

6

object named as

Cynthia Toth

1 reference

2 August 2017

Gui-shuang Ying

1

1 reference

2 August 2017

Jiayan Huang

2

1 reference

2 August 2017

Maureen G Maguire

3

1 reference

2 August 2017

Glenn J Jaffe

4

1 reference

2 August 2017

Juan E Grunwald

5

1 reference

2 August 2017

Michael Klein

8

1 reference

2 August 2017

Dante Pieramici

9

1 reference

2 August 2017

John Wells

10

1 reference

2 August 2017

Daniel F Martin

11

1 reference

2 August 2017

Comparison of Age-related Macular Degeneration Treatments Trials Research Group

12

1 reference

2 August 2017

publication date

6 October 2012

1 reference

2 August 2017

1 reference

2 August 2017

volume

120

1 reference

2 August 2017

issue

1

1 reference

2 August 2017

page(s)

122-129

1 reference

Ranibizumab and bevacizumab for neovascular age-related macular degeneration

2 August 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Characteristics of patients losing vision after 2 years of monthly dosing in the phase III ranibizumab clinical trials

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Ranibizumab monotherapy for sub-foveal haemorrhage secondary to choroidal neovascularisation in age-related macular degeneration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Ranibizumab versus verteporfin for neovascular age-related macular degeneration.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Ranibizumab for neovascular age-related macular degeneration

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Optical coherence tomography findings after an intravitreal injection of bevacizumab (avastin) for neovascular age-related macular degeneration.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration.

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Ranibizumab for predominantly classic neovascular age-related macular degeneration: subgroup analysis of first-year ANCHOR results

6 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Subgroup analysis of the MARINA study of ranibizumab in neovascular age-related macular degeneration

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

Intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

A computerized method of visual acuity testing: adaptation of the early treatment of diabetic retinopathy study testing protocol

27 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3536921

10.1016/J.OPHTHA.2012.07.042

27 October 2018

Identifiers

DOI

1 reference

2 August 2017

1 reference

2 August 2017

1 reference